Lorundrostat (developmental name MLS 101) is an aldosterone synthase inhibitor developed by Mineralys Therapeutics for high blood pressure. In clinical trials as an add-on medication for people with uncontrolled hypertension, decreased renin and elevated aldosterone it significantly reduced blood pressure. Hyperkalemia occurred in some trial participants.
In a meta-analysis analysing data from 3 randomized controlled trials over 3 months of clinical use, lorundrostat at 50-100mg/day was found to be effective in lowering blood pressure, with associated issues of mild increase in serum potassium levels and decline in the glomerular filtration rate
References